92 related articles for article (PubMed ID: 1936874)
1. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
Cirkel U; Ochs H; Latussek B; Schneider HP
Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
[TBL] [Abstract][Full Text] [Related]
2. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
4. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
6. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
7. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
9. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
10. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
11. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
13. [The value of tumor markers in colorectal cancer].
Peters KM; Grundmann R
Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
15. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
18. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
20. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]